Whenever you hear someone from Pharma talk about healthcare in China, you're sure to hear the phrase 'emerging market'. Within the industry there has been a Klondike style gold rush running for several years.
Without question, in established markets such as EU big five and North America - as product pipelines constrict and marketing authorisation expiry appears on the horizon for some of the traditional cash cows - the wagon train heading east has gathered pace.
The commercial reality is that these particular prospectors have needed more than a gold pan and luck. Heavy investment in manufacturing and sales infrastructure, running into hundreds or thousands of millions of Euros has been the pre-requisite.